Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
Status:
Completed
Trial end date:
2020-08-27
Target enrollment:
Participant gender:
Summary
This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of
ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health
Organization (WHO) grade III or IV malignant glioma.